BR100 Increased By (0.75%)
BR30 Increased By (1.08%)
KSE100 Increased By (0.82%)
KSE30 Increased By (0.89%)
AGHA 6.44 Increased By ▲ 0.06 (0.94%)
BECO 4.33 Decreased By ▼ -0.02 (-0.46%)
BML 62.90 Increased By ▲ 0.35 (0.56%)
BOP 31.42 Increased By ▲ 0.03 (0.1%)
CNERGY 11.90 Increased By ▲ 0.17 (1.45%)
CSIL 5.90 Decreased By ▼ -0.01 (-0.17%)
FCCL 62.29 Increased By ▲ 0.58 (0.94%)
FFL 14.87 Increased By ▲ 0.08 (0.54%)
FNEL 1.29 Increased By ▲ 0.05 (4.03%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.90 No Change ▼ 0.00 (0%)
LOTCHEM 24.78 Increased By ▲ 0.09 (0.36%)
MLCF 106.03 Increased By ▲ 2.10 (2.02%)
NBP 174.59 Increased By ▲ 1.27 (0.73%)
NCPL 52.30 Increased By ▲ 0.47 (0.91%)
NPL 55.00 Increased By ▲ 0.97 (1.8%)
OGDC 319.93 Increased By ▲ 4.06 (1.29%)
PACE 9.33 Increased By ▲ 0.07 (0.76%)
PAEL 35.87 Increased By ▲ 0.29 (0.82%)
PIBTL 13.90 Increased By ▲ 0.24 (1.76%)
PPL 228.51 Increased By ▲ 2.44 (1.08%)
PRL 81.91 Increased By ▲ 1.63 (2.03%)
PTC 47.19 Increased By ▲ 0.55 (1.18%)
SSGC 24.01 Increased By ▲ 0.19 (0.8%)
TBL 9.26 Increased By ▲ 0.02 (0.22%)
TELE 7.53 Decreased By ▼ -0.02 (-0.26%)
TPL 25.00 Increased By ▲ 0.46 (1.87%)
TPLP 13.15 Increased By ▲ 0.16 (1.23%)
TREET 26.11 Increased By ▲ 0.13 (0.5%)
TRG 53.80 Increased By ▲ 0.47 (0.88%)
World

Sinopharm COVID-19 booster weaker against Omicron: study

Published Updated
By

BEIJING: A COVID-19 booster shot produced by China's Sinopharm had "significantly lower" neutralising activity against the Omicron variant, Chinese researchers said in a paper, although they added the vaccine's efficacy against Omicron remained unclear.

The study - conducted by researchers from Shanghai Jiao Tong University and a Shanghai-based lab specializing in respiratory infectious diseases - compared the activity of Sinopharm's booster vaccine against an older coronavirus strain from Wuhan.

The neutralising antibody activity of a Sinopharm BBIBP-CorV booster against Omicron showed a 20.1-fold reduction, compared with its activity against a Wuhan strain, according to the paper published on Saturday.

J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron: study

Sinopharm did not immediately respond to a request for comment.

Sinopharm's BBIBP-CorV vaccine and Sinovac Biotech's CoronaVac are the two most used vaccines in China and are the leading COVID-19 vaccines exported by the country. Sinopharm also has a second vaccine in use in China.

The study analysed samples from 292 healthcare workers who received a third dose, or booster shot, about eight to nine months after their second dose. After a further four weeks, serum samples from 78.1% participants retained neutralising activity against Omicron, researchers said in a paper that has not been peer reviewed.

However, the study authors cautioned the results were not equal to how well a Sinopharm booster could shield recipients from diseases caused by Omicron, as neutralisation is only part of the human immune response.

The testing against the earlier Wuhan strain showed that about eight to nine months after the second BBIBP-CorV shot, the neutralizing activity "could hardly be detected", while the booster lifted the response significantly, according to the paper Reuters

Comments

Comments are closed for this article.